Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers
Authors:
Open Access
- 16 February 2022
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 41 (14) , 2039-2053
Abstract
Primary liver cancer (PLC) comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) represents the third deadliest cancer worldwide with still insufficient treatment options. We have previously found that CD4 T helper 1 (Th1) response is indispensable for the protection against PLC. In the present research, we aimed to test the potent inducers of Th1 responses, live-attenuated Listeria monocytogenes ∆actA/∆inlB strain as preventive/therapeutic vaccine candidate in liver fibrosis, HCC, and CCA. Studies were performed using autochthonous models of HCC and CCA, highly reflecting human disease. L. monocytogenes ∆actA/∆inlB demonstrated strong safety/efficacy in premalignant and malignant liver diseases. The protective mechanism relied on the induction of strong tumor-specific immune responses that keep the development of hepatobiliary cancers under control. Combination therapy, comprising Listeria vaccination and a checkpoint inhibitor blockade significantly extended the survival of HCC-bearing mice even at the advanced stages of the disease. This is the first report on the safety and efficacy of Listeria-based vaccine in liver fibrosis, as well as the first proof of principle study on Listeria-based vaccines in CCA. Our study paves the way for the use of live-attenuated Listeria as safe and efficient vaccine and a potent inducer of protective immune responses in liver fibrosis and hepatobiliary malignancies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (YE 151/2-1, LO-1676/4-1)
- Fritz Thyssen Stiftung (REF.10.16.1.031MN)
- Young Academy MHH (TY), HiLFII MHH (TY), Ellen Schmidt Program MHH (TY), Niedersächsische Krebsgesellschaft e.V. (grant to TY).
- Deutscher Akademischer Austauschdienst (Project-ID 91736778)
- Wilhelm Sander-Stiftung (2013.107.1)
This publication has 46 references indexed in Scilit:
- Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of LiverAdvances in Virology, 2013
- Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma developmentOncoImmunology, 2012
- Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologiesCarcinogenesis, 2012
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer developmentNature, 2011
- Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinomaOncogene, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Response to Hepatitis A and B Vaccine Alone or in Combination in Patients with Chronic Hepatitis C Virus and Advanced FibrosisDigestive Diseases and Sciences, 2009
- An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse ModelThe Journal of Immunology, 2009
- Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer ImmunotherapyClinical and Vaccine Immunology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008